MADRIGAL PHARMACEUTICALS INC (MDGL) Fundamental Analysis & Valuation

NASDAQ:MDGL • US5588681057

Current stock price

511.89 USD
-21.99 (-4.12%)
At close:
520 USD
+8.11 (+1.58%)
After Hours:

This MDGL fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MDGL Profitability Analysis

1.1 Basic Checks

  • In the past year MDGL has reported negative net income.
  • In the past year MDGL has reported a negative cash flow from operations.
  • MDGL had negative earnings in each of the past 5 years.
  • MDGL had a negative operating cash flow in each of the past 5 years.
MDGL Yearly Net Income VS EBIT VS OCF VS FCFMDGL Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -100M -200M -300M -400M

1.2 Ratios

  • MDGL has a Return On Assets of -22.89%. This is in the better half of the industry: MDGL outperforms 73.31% of its industry peers.
  • Looking at the Return On Equity, with a value of -47.83%, MDGL is in the better half of the industry, outperforming 63.64% of the companies in the same industry.
Industry RankSector Rank
ROA -22.89%
ROE -47.83%
ROIC N/A
ROA(3y)-41.97%
ROA(5y)-59.17%
ROE(3y)-67.26%
ROE(5y)-94.94%
ROIC(3y)N/A
ROIC(5y)N/A
MDGL Yearly ROA, ROE, ROICMDGL Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -50 -100

1.3 Margins

  • MDGL's Gross Margin of 94.14% is amongst the best of the industry. MDGL outperforms 95.55% of its industry peers.
  • MDGL does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 94.14%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MDGL Yearly Profit, Operating, Gross MarginsMDGL Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -100 -200

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

4

2. MDGL Health Analysis

2.1 Basic Checks

  • MDGL does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, MDGL has more shares outstanding
  • The number of shares outstanding for MDGL has been increased compared to 5 years ago.
  • Compared to 1 year ago, MDGL has a worse debt to assets ratio.
MDGL Yearly Shares OutstandingMDGL Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M
MDGL Yearly Total Debt VS Total AssetsMDGL Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

2.2 Solvency

  • An Altman-Z score of 9.73 indicates that MDGL is not in any danger for bankruptcy at the moment.
  • MDGL's Altman-Z score of 9.73 is amongst the best of the industry. MDGL outperforms 80.66% of its industry peers.
  • MDGL has a Debt/Equity ratio of 0.56. This is a neutral value indicating MDGL is somewhat dependend on debt financing.
  • MDGL's Debt to Equity ratio of 0.56 is on the low side compared to the rest of the industry. MDGL is outperformed by 71.37% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Altman-Z 9.73
ROIC/WACCN/A
WACC9.19%
MDGL Yearly LT Debt VS Equity VS FCFMDGL Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M -200M 400M -400M 600M

2.3 Liquidity

  • MDGL has a Current Ratio of 4.01. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Current ratio, with a value of 4.01, MDGL is in line with its industry, outperforming 47.78% of the companies in the same industry.
  • MDGL has a Quick Ratio of 3.77. This indicates that MDGL is financially healthy and has no problem in meeting its short term obligations.
  • MDGL's Quick ratio of 3.77 is in line compared to the rest of the industry. MDGL outperforms 48.74% of its industry peers.
Industry RankSector Rank
Current Ratio 4.01
Quick Ratio 3.77
MDGL Yearly Current Assets VS Current LiabilitesMDGL Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 200M 400M 600M 800M 1B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. MDGL Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 42.33% over the past year.
  • The Revenue has grown by 432.05% in the past year. This is a very strong growth!
EPS 1Y (TTM)42.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.17%
Revenue 1Y (TTM)432.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%210.77%

3.2 Future

  • MDGL is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 53.72% yearly.
  • MDGL is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 38.18% yearly.
EPS Next Y62.32%
EPS Next 2Y71.25%
EPS Next 3Y66.97%
EPS Next 5Y53.72%
Revenue Next Year56.73%
Revenue Next 2Y51.84%
Revenue Next 3Y47.12%
Revenue Next 5Y38.18%

3.3 Evolution

MDGL Yearly Revenue VS EstimatesMDGL Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B
MDGL Yearly EPS VS EstimatesMDGL Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 50 100 150

More info and screens

Find the best growth stocksShow best growing peers

1

4. MDGL Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for MDGL. In the last year negative earnings were reported.
  • Also next year MDGL is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
MDGL Price Earnings VS Forward Price EarningsMDGL Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 50 -50 -100

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MDGL Per share dataMDGL EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 -10 20 30 40

4.3 Compensation for Growth

  • A more expensive valuation may be justified as MDGL's earnings are expected to grow with 66.97% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y71.25%
EPS Next 3Y66.97%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MDGL Dividend Analysis

5.1 Amount

  • No dividends for MDGL!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MDGL Fundamentals: All Metrics, Ratios and Statistics

MADRIGAL PHARMACEUTICALS INC

NASDAQ:MDGL (4/7/2026, 8:50:06 PM)

After market: 520 +8.11 (+1.58%)

511.89

-21.99 (-4.12%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-19
Earnings (Next)04-29
Inst Owners96.64%
Inst Owner Change0%
Ins Owners1.15%
Ins Owner Change4.05%
Market Cap11.74B
Revenue(TTM)958.40M
Net Income(TTM)-288.28M
Analysts81.74
Price Target672.72 (31.42%)
Short Float %18.57%
Short Ratio10.6
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-203.8%
Min EPS beat(2)-274%
Max EPS beat(2)-133.61%
EPS beat(4)2
Avg EPS beat(4)-86.34%
Min EPS beat(4)-274%
Max EPS beat(4)48.79%
EPS beat(8)5
Avg EPS beat(8)-35.67%
EPS beat(12)6
Avg EPS beat(12)-23.45%
EPS beat(16)7
Avg EPS beat(16)-18.84%
Revenue beat(2)2
Avg Revenue beat(2)7.31%
Min Revenue beat(2)0.74%
Max Revenue beat(2)13.88%
Revenue beat(4)4
Avg Revenue beat(4)15.34%
Min Revenue beat(4)0.74%
Max Revenue beat(4)28.53%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.14%
PT rev (3m)10.09%
EPS NQ rev (1m)-23.83%
EPS NQ rev (3m)-408.2%
EPS NY rev (1m)-556.56%
EPS NY rev (3m)-384.77%
Revenue NQ rev (1m)-0.6%
Revenue NQ rev (3m)-1.3%
Revenue NY rev (1m)2.36%
Revenue NY rev (3m)3.13%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 12.25
P/FCF N/A
P/OCF N/A
P/B 19.48
P/tB 19.73
EV/EBITDA N/A
EPS(TTM)-12.75
EYN/A
EPS(NY)-4.8
Fwd EYN/A
FCF(TTM)-8.41
FCFYN/A
OCF(TTM)-8.26
OCFYN/A
SpS41.78
BVpS26.27
TBVpS25.95
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -22.89%
ROE -47.83%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 94.14%
FCFM N/A
ROA(3y)-41.97%
ROA(5y)-59.17%
ROE(3y)-67.26%
ROE(5y)-94.94%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.76
Health
Industry RankSector Rank
Debt/Equity 0.56
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 230.21%
Cap/Sales 0.36%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 4.01
Quick Ratio 3.77
Altman-Z 9.73
F-Score3
WACC9.19%
ROIC/WACCN/A
Cap/Depr(3y)366.82%
Cap/Depr(5y)239.7%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)42.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%5.17%
EPS Next Y62.32%
EPS Next 2Y71.25%
EPS Next 3Y66.97%
EPS Next 5Y53.72%
Revenue 1Y (TTM)432.05%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%210.77%
Revenue Next Year56.73%
Revenue Next 2Y51.84%
Revenue Next 3Y47.12%
Revenue Next 5Y38.18%
EBIT growth 1Y39.72%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year33.22%
EBIT Next 3Y77.55%
EBIT Next 5YN/A
FCF growth 1Y58.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y58.39%
OCF growth 3YN/A
OCF growth 5YN/A

MADRIGAL PHARMACEUTICALS INC / MDGL Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MADRIGAL PHARMACEUTICALS INC (MDGL) stock?

ChartMill assigns a fundamental rating of 3 / 10 to MDGL.


Can you provide the valuation status for MADRIGAL PHARMACEUTICALS INC?

ChartMill assigns a valuation rating of 1 / 10 to MADRIGAL PHARMACEUTICALS INC (MDGL). This can be considered as Overvalued.


What is the profitability of MDGL stock?

MADRIGAL PHARMACEUTICALS INC (MDGL) has a profitability rating of 2 / 10.